Phase II study of 5-fluorouracil –leucovorin plus bevacizumab for chemotherapy-naïve older or frail patients with metastatic colorectal cancer (OGSG 0802)

ConclusionWeekly 5-FU –leucovorin with biweekly bevacizumab may be a tolerable and effective treatment option for older or frail patients with mCRC.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research